Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related …


Apitope receives 12 million euros from Wales

The Belgian-British biotech company Apitope, which started as a spin-off of the Hasselt University in Diepenbeek, gets 12 million euros from an in…


23,5 million euro for a cutting-edge allergy treatment

ASIT Biotech, a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of breakthrough immunothe…

POPULAR TAGS

Galapagos thinks big

Written by DS on in the category news with the tags , .


Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary rights of GLPG1205 and GLPG1690, two molecules under development for ulcerative colitis and idiopathic pulmonary fibrosis respectively. Elisabeth Goodwin, head of corporate communications at Galapagos, explains: “We try to have as many  fully proprietary assets as possible. By regaining the rights of the components in co-development with Janssen, we head in that direction. Janssen still benefits from Galapagos’ success, as J&J still possesses 8% of Galapagos.” The Phase 2B results of Filgotinib, the flagship product of Galapagos for the treatment of rheumatoid arthritis, are expected April 2015. “Abbvie (North Chicago, IL) will have the opportunity to license  this product. That will yield $200 million in our bank account. A phase 2 study is also ongoing with Filgotinib for Crohn’s disease. These results are expected at the end of the year. If Abbvie buys the license for Crohn’s disease too, we receive an additional $50 million. This does not even include the royalties that we will receive on top of that, which might be more than $1 billion,” adds Elisabeth.


Galapagos is also developing a treatment for patients with cystic fibrosis. It is working on a next-generation, triple combination therapy, and will be the only competitor of Vertex (Boston, MA). Currently, Vertex is the only company with an approved drug to treat the cause of cystic fibrosis. “Our cystic fibrosis product will be better than that of Vertex”, claims Elisabeth, “our next-generation therapy will be able to treat 90% of the people, whereas that of Vertex will be able to help only 80% of the patients. Vertex’s cystic fibrosis product is worth $30 million. This is huge.” When asked if they want to be bought by a big pharma concern, Elisabeth replies: “Not at all. In the beginning, partnering was very important for financing, enforcement and validation, and made us to what we are today."

We have the ambition to independently grow and become the biggest and most successful biotech company.

"We hope at some point to develop, produce and bring the products for inflammation, mucoviscidosis and fibrosis to the patient ourselves.” Galapagos plans to collect $100 million with its IPO at NASDAQ.

Read more about: , .

RELATED ARTICLES
Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related …


Apitope receives 12 million euros from Wales

The Belgian-British biotech company Apitope, which started as a spin-off of the Hasselt University in Diepenbeek, gets 12 million euros from an in…


23,5 million euro for a cutting-edge allergy treatment

ASIT Biotech, a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of breakthrough immunothe…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

KU Leuven XpandInnovation Biowin GSK Flanders.bio Turnstone UGent V-Bio Ventures Janssen Itera Life Science

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.